NASDAQ:EVLO

Evelo Biosciences Stock Forecast, Price & News

$11.56
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.10
Now: $11.56
$11.91
50-Day Range
$9.71
MA: $11.45
$13.69
52-Week Range
$3.55
Now: $11.56
$19.93
Volume175,606 shs
Average Volume276,802 shs
Market Capitalization$616.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Evelo Biosciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVLO
CUSIPN/A
Phone617-577-0300
Employees90
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.88 per share

Profitability

Net Income$-85,470,000.00

Miscellaneous

Market Cap$616.55 million
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable

Headlines

Evelo Biosciences (NASDAQ:EVLO) Trading Up 6.9%
April 15, 2021 |  americanbankingnews.com
Evelo Biosciences (NASDAQ:EVLO) Shares Down 4.7%
April 14, 2021 |  americanbankingnews.com
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $10.04
April 12, 2021 |  americanbankingnews.com
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $10.37
March 31, 2021 |  americanbankingnews.com
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down to $11.31
March 29, 2021 |  americanbankingnews.com
Evelo Biosciences (NASDAQ:EVLO) Stock Price Down 5.3%
March 25, 2021 |  americanbankingnews.com
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $13.35
March 23, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

79th out of 2,025 stocks

Pharmaceutical Preparations Industry

33rd out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
$11.56
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

Is Evelo Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evelo Biosciences stock.
View analyst ratings for Evelo Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Evelo Biosciences?

Wall Street analysts have given Evelo Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evelo Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Evelo Biosciences
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its earnings results on Monday, March, 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.14.
View Evelo Biosciences' earnings history
.

How has Evelo Biosciences' stock price been impacted by Coronavirus?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EVLO stock has increased by 164.5% and is now trading at $11.56.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EVLO?

5 analysts have issued 1 year target prices for Evelo Biosciences' stock. Their forecasts range from $14.00 to $36.00. On average, they anticipate Evelo Biosciences' share price to reach $20.00 in the next year. This suggests a possible upside of 73.0% from the stock's current price.
View analysts' price targets for Evelo Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Dr. Balkrishan Gill, Pres, CEO, Treasurer, Principal Financial Officer & Director (Age 56)
  • Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 63)
  • Ms. Xiaoli Liu, Controller & Principal Accounting Officer (Age 46)
  • Dr. Chun Zhang, Head of Technical Operations
  • Mr. Stefan Riley, Head of Investor Relations
  • Mr. Daniel S. Char, Gen. Counsel & Sec. (Age 60)
  • Ms. Jessica Cotrone, VP & Head of Communications
  • Ms. Julie Carretero, Chief People Officer
  • Dr. Andrea Itano Ph.D., Head of Research
  • Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 54)

Who are some of Evelo Biosciences' key competitors?

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $11.56.

How much money does Evelo Biosciences make?

Evelo Biosciences has a market capitalization of $616.55 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis.

How many employees does Evelo Biosciences have?

Evelo Biosciences employs 90 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

Where are Evelo Biosciences' headquarters?

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.